Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M16.8Revenue (TTM) $M0.8Net Margin (%)-2,855.9Altman Z-Score-64.7
Enterprise Value $M10.0EPS (TTM) $-2.8Operating Margin %-3,193.4Piotroski F-Score1
P/E(ttm)--Beneish M-Score-6.9Pre-tax Margin (%)-2,854.2Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.0Cash flow > EarningsN
Price/Sales16.45-y EBITDA Growth Rate %--Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-125.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-4,410.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONTX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ONTX is held by these investors:



ONTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bienen Henry SDirector 2017-04-26Buy3,810$2.1-19.05view
Guerin Mark PatrickCFO 2017-04-26Buy1,429$2.1-19.05view
MARINO JAMES JDirector 2017-04-26Buy11,906$2.1-19.05view
Reddy E PremkumarDirector 2017-04-26Buy119,048$2.1-19.05view
Kumar RameshPresident and CEO 2017-04-26Buy23,810$2.1-19.05view
Michael & Jane Hoffman 2013 De10% Owner 2014-02-21Buy14,348$84.7-97.99view
Hoffman Michael BDirector, 10% Owner 2014-02-21Buy14,348$84.7-97.99view
Kumar RameshPresident and CEO 2014-02-10Sell3,354$150.7-98.87view
Kumar RameshPresident and CEO 2014-02-03Sell6,000$150.5-98.87view
Hoffman Michael BDirector, 10% Owner 2014-01-27Buy5,730$119.2-98.57view

Press Releases about ONTX :

Quarterly/Annual Reports about ONTX:

    News about ONTX:

    Articles On GuruFocus.com
    Onconova Therapeutics to Present at the LD Micro Conference in December Nov 20 2017 
    Onconova Therapeutics to Present at the LD Micro Conference in December Nov 20 2017 
    Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/ Nov 16 2017 
    Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patient Nov 15 2017 
    Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patient Nov 15 2017 
    Onconova Therapeutics Announces Pricing of Public Offering of Common Stock Nov 10 2017 
    Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results Nov 02 2017 
    Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annu Nov 01 2017 
    Onconova Therapeutics to Present Updates at Two Investor Conferences in October Oct 10 2017 
    Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pe Oct 04 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK